Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senior management changes at Aastrom Biosciences

This article was originally published in Scrip

Executive Summary

Aastrom Biosciences (US) has announced that its CEO, president, chief financial officer and director, George Dunbar, will move out of day-to-day management duties and is expected to assume the role of chairman after the company's annual meeting of shareholders, which is planned for December 14th. Timothy Mayleben, a member of the company's board of directors and chair of the audit committee, will remain as a director and will become the Aastrom's new CEO, president and CFO in December. Nelson Sims, who has served as chairman since October 2008, is expected to assume the role of lead director.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC004341

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel